|Molecular portraits of human breast tumours|
CM Perou, T Sørlie, MB Eisen, M Van De Rijn, SS Jeffrey, CA Rees, ...
nature 406 (6797), 747-752, 2000
|Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications|
T Sørlie, CM Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, ...
Proceedings of the National Academy of Sciences 98 (19), 10869-10874, 2001
|Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors|
JR Pollack, T Sørlie, CM Perou, CA Rees, SS Jeffrey, PE Lonning, ...
Proceedings of the National Academy of Sciences 99 (20), 12963-12968, 2002
|Database of p53 gene somatic mutations in human tumors and cell lines.|
M Hollstein, K Rice, MS Greenblatt, T Soussi, R Fuchs, T Sørlie, E Hovig, ...
Nucleic acids research 22 (17), 3551, 1994
|Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival|
HY Chang, DSA Nuyten, JB Sneddon, T Hastie, R Tibshirani, T Sørlie, ...
Proceedings of the national academy of sciences 102 (10), 3738-3743, 2005
|Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer|
A Bergamaschi, YH Kim, P Wang, T Sørlie, T Hernandez‐Boussard, ...
Genes, Chromosomes and Cancer 45 (11), 1033-1040, 2006
|Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms|
T Sørlie, Y Wang, C Xiao, H Johnsen, B Naume, RR Samaha, ...
BMC genomics 7 (1), 1-15, 2006
|Molecular portraits of breast cancer: tumour subtypes as distinct disease entities|
European journal of cancer 40 (18), 2667-2675, 2004
|Gene expression patterns in ovarian carcinomas|
ME Schaner, DT Ross, G Ciaravino, T Sørlie, O Troyanskaya, M Diehn, ...
Molecular biology of the cell 14 (11), 4376-4386, 2003
|Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome|
A Bergamaschi, E Tagliabue, T Sørlie, B Naume, T Triulzi, R Orlandi, ...
The Journal of pathology 214 (3), 357-367, 2008
|Triple-negative breast cancer: present challenges and new perspectives|
F Podo, LMC Buydens, H Degani, R Hilhorst, E Klipp, IS Gribbestad, ...
Molecular oncology 4 (3), 209-229, 2010
|Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53 mutant Her2 and triple negative breast cancer|
R Sainsbury, I Proctor, S Rodriguez, M Loddo, S Tudzarova, K Stoeber, ...
Breast cancer research 12 (1), 1-2, 2010
|Cell-type-specific responses to chemotherapeutics in breast cancer|
MA Troester, KA Hoadley, T Sørlie, BS Herbert, AL Børresen-Dale, ...
Cancer Research 64 (12), 4218-4226, 2004
|Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer|
AA Muggerud, JA Rønneberg, F Wärnberg, J Botling, F Busato, ...
Breast Cancer Research 12 (1), 1-10, 2010
|Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling|
VN Kristensen, CJ Vaske, J Ursini-Siegel, P Van Loo, SH Nordgard, ...
Proceedings of the National Academy of Sciences 109 (8), 2802-2807, 2012
|Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression|
IO Potapenko, VD Haakensen, T Lüders, Å Helland, I Bukholm, T Sørlie, ...
Molecular oncology 4 (2), 98-118, 2010
|Genomic architecture characterizes tumor progression paths and fate in breast cancer patients|
HG Russnes, HKM Vollan, OC Lingjærde, A Krasnitz, P Lundin, B Naume, ...
Science translational medicine 2 (38), 38ra47-38ra47, 2010
|Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer|
T Sørlie, CM Perou, C Fan, S Geisler, T Aas, A Nobel, G Anker, LA Akslen, ...
Molecular cancer therapeutics 5 (11), 2914-2918, 2006
|Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer|
B Naume, X Zhao, M Synnestvedt, E Borgen, HG Russnes, OC Lingjærde, ...
Molecular oncology 1 (2), 160-171, 2007
|Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models|
A Bergamaschi, GO Hjortland, T Triulzi, T Sørlie, H Johnsen, AH Ree, ...
Molecular oncology 3 (5-6), 469-482, 2009